Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 41 to 50 of 480 total matches.

Dasiglucagon (Zegalogue) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
, an intranasal powder approved for use in patients ≥4 years old, have been available since 2019.1,2 Injectable ...
The FDA has approved dasiglucagon (Zegalogue – Zealand) for subcutaneous (SC) treatment of severe hypoglycemia in patients ≥6 years old with diabetes. Dasiglucagon is the third glucagon product to be marketed in the US that does not require reconstitution before administration; Gvoke, a SC formulation approved for use in patients ≥2 years old, and Baqsimi, an intranasal powder approved for use in patients ≥4 years old, have been available since 2019. Injectable glucagon emergency kits (GlucaGen HypoKit, and generics) have been available for years, but they require reconstitution of...
Med Lett Drugs Ther. 2021 Aug 23;63(1631):132-4 | Show Introduction Hide Introduction

Two New Drugs for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
effective and may be better tolerated. The 0.1% formulation of the drug is better tolerated than higher ...
The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod (Vyzulta – Bausch and Lomb), a modified prostaglandin analog, and netarsudil (VRhopressa – Aerie), the first Rho kinase inhibitor to be approved in the US.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):117-20 | Show Introduction Hide Introduction

Ozanimod (Zeposia) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021  (Issue 1633)
Ozanimod (Zeposia) for Ulcerative Colitis The oral sphingosine 1-phosphate (S1P) receptor ...
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod (Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):147-51 | Show Introduction Hide Introduction

Correction: Drugs for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017  (Issue 1529)
as stated in footnote 1. The footnote has been corrected and the price of the generic formulation ...
In Table 3 on page 116 (Med Lett Drugs Ther 2017; 59:113), the price provided for Prevpac was for a 14-day supply, rather than for a 10-day supply as stated in footnote 1. The footnote has been corrected and the price of the generic formulation of Prevpac has been added.
Med Lett Drugs Ther. 2017 Sep 11;59(1529):154 | Show Introduction Hide Introduction

Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017  (Issue 1535)
cancer. Nivolumab (Opdivo) and atezolizumab (Tecentriq) were approved earlier for this indication.1 ...
The FDA has approved avelumab (Bavencio – EMD Serono) and durvalumab (Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab (Keytruda – Merck), a checkpoint inhibitor that has been available in the US since 2014, for treatment of locally advanced or metastatic bladder cancer. Nivolumab (Opdivo) and atezolizumab (Tecentriq) were approved earlier for this indication.
Med Lett Drugs Ther. 2017 Dec 4;59(1535):e202-203 | Show Introduction Hide Introduction

Correction: Abuse-Deterrent Opioids

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
-deterrent opioids, the information on Targiniq ER in Table 1 is incorrect. The drug, which is not available ...
In our article on abuse-deterrent opioids (Med Lett Drugs Ther 2017; 59:95), the information on Targiniq ER in Table 1 is incorrect. The drug, which is not available in the US, is a combination of oxycodone ER and naloxone, not naltrexone, and naloxone is dispersed throughout the tablet, not sequestered. Targiniq ER will be deleted from the table in the article as it appears on our website.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):122 | Show Introduction Hide Introduction

An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020  (Issue 1612)
for progressing to severe disease and/or hospitalization (see Table 1).1 Monoclonal antibodies ...
The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table 1).
Med Lett Drugs Ther. 2020 Nov 30;62(1612):185-6 | Show Introduction Hide Introduction

In Brief: Another Insulin Lispro (Admelog) for Diabetes (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018  (Issue 1549)
. In SORELLA 11 in 507 patients with type 1 diabetes and SORELLA 22 in 505 patients with type 2 diabetes ...
The FDA has approved Admelog (Sanofi-Aventis), an insulin lispro product similar to Humalog (Lilly), which went off patent in 2013.Approval of Admelog was based on efficacy data with Humalog and on two 6-month, open-label, randomized, noninferiority trials. In SORELLA 11 in 507 patients with type 1 diabetes and SORELLA 22 in 505 patients with type 2 diabetes, Admelog was noninferior to Humalog in lowering A1C, fasting plasma glucose levels, and self-monitored plasma glucose levels. The incidence of adverse effects, including hypoglycemia, was similar.Even though Admelog is very similar to...
Med Lett Drugs Ther. 2018 Jun 18;60(1549):e109 | Show Introduction Hide Introduction

Trifarotene (Aklief) - A New Topical Retinoid for Acne

   
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019  (Issue 1587)
by prescription for decades. Adapalene 0.1% gel has been available over the counter since 2016 for treatment ...
The FDA has approved trifarotene 0.005% cream (Aklief – Galderma) for topical treatment of acne vulgaris in patients ≥9 years old. Trifarotene is the fourth topical retinoid to be approved in the US for treatment of acne; tretinoin (Retin-A, and others), adapalene (Differin, and generics), and tazarotene (Tazorac, and others) have been available by prescription for decades. Adapalene 0.1% gel has been available over the counter since 2016 for treatment of acne in patients ≥12 years old.
Med Lett Drugs Ther. 2019 Dec 16;61(1587):195-7 | Show Introduction Hide Introduction

In Brief: Hydrochlorothiazide and Skin Cancer

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
carcinoma [SCC]) to the labels of products containing the diuretic hydrochlorothiazide.1 The labeling ...
The FDA has required the addition of information about an increased risk of nonmelanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) to the labels of products containing the diuretic hydrochlorothiazide.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):177 | Show Introduction Hide Introduction